Senti Biosciences Holdings (SNTI): Insider filed to sell ~$319K
New Enterprise Associates 15, Insider at Senti Biosciences Holdings, filed to sell ~$319K of Senti Biosciences Holdings shares.
- ~$319K
- planned to sell · 114K shares, around Nov 20, 2026
- Planned for
- Nov 20, 2026
- Notice filed
- Nov 20, 2026
What stands out in this filing
- The planned sale is 0.13% of the company's shares outstanding, as stated on the notice.
- How the shares were acquired, per the notice: Private Placement.
- Broker named on the notice: J.P. Morgan Securities LLC.
- A Form 144 announces a sale; the Form 4 that follows shows whether it took place, at what price.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 23, 2026, Brenda Cooperstone, Ph.D., notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of her decision to resign from the Board, effective immediately.”
- Oct 21, 2026Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“The information provided in the Introductory Note and Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Celadon Partners, LLC (“Celadon”) controls Parent, Celadon Partners SPV 24 Limited, the Company’s largest stockholder, CPIF II-7 Limited, which purchased $14.0 million in aggregate principal amount of Midco’s Senior Secured Convertible Notes, and the Investor.”
- Oct 26, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 27, 2026, Edward Mathers notified the Board of Directors (the "Board") of Senti Biosciences Holdings, Inc. (the "Company") of his decision to resign from the Board, effective immediately.”
- Nov 9, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
- Nov 13, 20265% stakeNantahala Capital Management, LLC reported a passive stake (13G) of 4.1%
- Nov 18, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
- Nov 18, 20265% stakeBayer HealthCare LLC filed an activist stake (13D) of 6.9%
- Nov 18, 20265% stakeNew Enterprise Associates 15, L.P. filed an activist stake (13D) of 9.7%
- Nov 20, 2026Company filing · Form 8-K · Auditor changeChanged its auditor“Changes in Registrant’s Certifying Accountant.”
How to read SEC Form 144
Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.
Full guide: What is an SEC Form 144?
What else is on file for Senti Biosciences Holdings
For Senti Biosciences Holdings, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SNTI page.
How this filing works
Explore the data
Common questions
Which Senti Biosciences Holdings (SNTI) insider traded, and how much?
New Enterprise Associates 15, Insider at Senti Biosciences Holdings, filed to sell ~$319K of Senti Biosciences Holdings shares. 114K shares, Form 144 notice of a planned sale.
When did it happen, and when was it made public?
Planned for: Nov 20, 2026. Notice filed: Nov 20, 2026.
What stands out in this filing?
The planned sale is 0.13% of the company's shares outstanding, as stated on the notice. How the shares were acquired, per the notice: Private Placement. Broker named on the notice: J.P. Morgan Securities LLC.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 144, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Senti Biosciences Holdings recently?
For Senti Biosciences Holdings, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the SNTI page.
Does this mean SNTI stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Senti Biosciences Holdings
- SEC Schedule 13DNov 18, 2026
- SEC Schedule 13DNov 18, 2026
- SEC Schedule 13GNov 13, 2026
- SEC Form 4Feb 7, 2025
- SEC Form 4Feb 7, 2025
- SEC Form 4Feb 7, 2025
Everything OQRO holds on this company is on its SNTI page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
